Efficacy and Safety of Capmatinib Plus Nivolumab in Pretreated Patients with EGFR Wild-Type Non-Small Cell Lung Cancer

被引：0

作者：

Felip, E. ^{[1
]}

Minotti, V. ^{[2
]}

Tan, D. ^{[3
]}

Wolf, J. ^{[4
]}

Mark, M. ^{[5
]}

Boyer, M. ^{[6
]}

Hughes, B. ^{[7
,8
]}

Bearz, A. ^{[9
]}

Moro-Sibilot, D. ^{[10
]}

Le, X. ^{[11
]}

Vazquez, J. ^{[12
]}

Massuti, B. ^{[13
]}

Liu, N. ^{[14
]}

Hao, L. ^{[14
]}

Cheng, Y. ^{[14
]}

Tiedt, R. ^{[15
]}

Cobo, M. ^{[16
]}

机构：

[1] Vall DHebron Inst Oncol Vhio, Oncol Serv, Barcelona, Spain

[2] AO Perugia Osped S Maria Misericordia Loc S Andre, Perugia, Italy

[3] Natl Canc Ctr Singapore, Singapore, Singapore

[4] Univ Hosp Cologne, Ctr Integrated Oncol, Cologne, Germany

[5] Kantonsspital, Dept Hematol Oncol, Chur, Switzerland

[6] Chris OBrien Lifehouse, Med Oncol, Camperdown, ACT, Australia

[7] Prince Charles Hosp, Chermside, Qld, Australia

[8] Univ Queensland, Brisbane, Qld, Australia

[9] IRCCS Aviano, Aviano, Italy

[10] Ctr Hosp Univ Grenoble Alpes, Grenoble, France

[11] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[12] Hosp Clin Univ San Carlos, Madrid, Spain

[13] Hosp Gen Univ Alicante, Alicante, Spain

[14] Novartis Inst Biomed Res Co Ltd, Shanghai, Peoples R China

[15] Novartis Inst Biomed Res, Basel, Switzerland

[16] Hosp Univ Carlos Haya, Med Oncol Serv, Malaga, Spain

来源：

JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期

关键词：

PD-L1; inhibitor; MET inhibitor; advanced NSCLC;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P76.03

引用

页码：S585 / S586

页数：2

共 50 条

[21] Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients
Onoi, Keisuke
Yamada, Tadaaki
Morimoto, Kenji
Kawachi, Hayato
Tsutsumi, Rei
Takeda, Takayuki
Okada, Asuka
Tamiya, Nobuyo
Chihara, Yusuke
Shiotsu, Shinsuke
Takemura, Yoshizumi
Yamada, Takahiro
Hasegawa, Isao
Katayama, Yuki
Iwasaku, Masahiro
Tokuda, Shinsaku
Takayama, Koichi
TARGETED ONCOLOGY, 2024, 19 (03) : 411 - 421
[22] Clinical impact of amphiregulin expression in EGFR wild-type non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors
Chang, M.
Lee, J.
Jung, C.
Park, Y.
Ahn, J.
Park, K.
Ahn, M.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[23] Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease
Kanai, Osamu
Kim, Young Hak
Demura, Yoshiki
Kanai, Makiko
Ito, Tsuyoshi
Fujita, Kohei
Yoshida, Hironori
Akai, Masaya
Mio, Tadashi
Hirai, Toyohiro
THORACIC CANCER, 2018, 9 (07) : 847 - 855
[24] Efficacy and Safety of Nivolumab in Non-Small Cell Lung Cancer with Preexisting Interstitial Lung Disease
Kanai, O.
Kim, Y.
Demura, Y.
Kanai, M.
Fujita, K.
Yoshida, H.
Akai, M.
Mio, T.
Hirai, T.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2420 - S2420
[25] Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer
Sequist, Lecia, V
Gray, Jhanelle Elaine
Harb, Wael A.
Lopez-Chavez, Ariel
Doebele, Robert C.
Modiano, Manuel R.
Jackman, David Michael
Baggstrom, Maria Quintos
Atmaca, Akin
Felip, Enriqueta
Provencio, Mariano
Cobo, Manuel
Adiwijaya, Bambang
Kuesters, Geoffrey
Kamoun, Walid S.
Andreas, Karen
Pipas, J. Marc
Santillana, Sergio
Cho, Byoung Chul
Park, Keunchil
Shepherd, Frances A.
ONCOLOGIST, 2019, 24 (08): : 1095 - 1102
[26] Randomized Phase 2 Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer
Sequist, L.
Gray, J.
Harb, W.
Doebele, R.
Modiano, M.
Jackman, D.
Baggstrom, M.
Atmaca, A.
Felip, E.
Provencio, M.
Cobo Dols, M.
Adiwijaya, B.
Kuesters, G.
Kamoun, W.
Andreas, K.
Pipas, J.
Santillana, S.
Cho, B. C.
Park, K.
Shepherd, F.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S596 - S596
[27] Phase II Trial of Erlotinib Monotherapy for Pretreated Elderly Patients with Advanced EGFR Wild-Type Non-Small-Cell Lung Cancer
Minemura, Hiroyuki
Yokouchi, Hiroshi
Azuma, Keisuke
Hirai, Kenichiro
Sekine, Satoko
Oshima, Kengo
Kanazawa, Kenya
Tanino, Yoshinori
Inokoshi, Yayoi
Ishii, Taeko
Katsuura, Yutaka
Oishi, Akio
Ishida, Takashi
Munakata, Mitsuru
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S547 - S547
[28] Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells
Li, Amin
Cao, Weiya
Liu, Xueke
Zhang, Yinci
Ma, Yongfang
Xu, Ruyue
Zhang, Rongbo
Liu, Xinkuang
Zhou, Shuping
Wang, Ruikai
Liu, Jiachang
Tang, Xiaolong
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (07) : 1737 - 1749
[29] Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells
Amin Li
Weiya Cao
Xueke Liu
Yinci Zhang
Yongfang Ma
Ruyue Xu
Rongbo Zhang
Xinkuang Liu
Shuping Zhou
Ruikai Wang
Jiachang Liu
Xiaolong Tang
Journal of Cancer Research and Clinical Oncology, 2020, 146 : 1737 - 1749
[30] Sensitization of EGFR Wild-Type Non-Small Cell Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitor Erlotinib
Raimbourg, Judith
Joalland, Marie-Pierre
Cabart, Mathilde
de Plater, Ludmilla
Bouquet, Fanny
Savina, Ariel
Decaudin, Didier
Bennouna, Jaafar
Vallette, Francois M.
Lalier, Lisenn
MOLECULAR CANCER THERAPEUTICS, 2017, 16 (08) : 1634 - 1644

← 1 2 3 4 5 →